SciBase receives US patent approval for its micro-needle electrodes

SciBase, a Swedish medtech company that develops and markets a new technology for early detection of malignant melanoma, has received approval from the United States Patent and Trademark Office (USPTO) for its patent on micro-needle electrodes. This technology is already patented in 12 European countries, Australia and Canada. The patent expires 2023. 

SciBase’s point-of-care device Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Malignant melanoma is a fast growing type of skin cancer, which appears in the epidermis right under the cornified layer. Nevisense’s electrodes utilise microscopic needles that permit measurement of the electrical impedance in the skin layers, where malignant melanoma can appear. The technique is essential for detecting the early stages of skin cancer.

”Right now, Nevisense is in the regulatory approval process in theUnited States, and we see theUSas a future key market for us. The approval of this US patent is thus an important step in our comingUSexpansion. Electrodes with micro-needles can potentially be used to detect other types of cancer as well,” says Simon Grant, CEO of SciBase.

SciBase holds a total of 49 registered patents and currently have another 12 active patent applications pending in six patent families.

Skin cancer is the most common cancer in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75 percent) of deaths related to skin cancer, although it only accounts for 4 percent of all skin cancer cases. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. The key to management is early detection. 

For more information, please contact:

Simon Grant, CEO

Phone: +46 72 887 43 99

Email: simon.grant@scibase.com

About SciBase and Nevisense

SciBaseABis a Swedish medical technology company, headquartered in Stockholmthat has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Further information is available on www.scibase.com

Tags:

About Us

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result. A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisenseproduct and further information is also available on www.scibase.com.

Subscribe

Documents & Links